CJC-1295 DAC + Ipamorelin Stack Dosage Protocol
Multi-vial stack protocol combining CJC-1295 DAC (5 mg) with Ipamorelin (5 mg) for sustained GH release. Combined dosing schedule across two separate vials.
Dosage Schedule
| Period | Dose |
|---|---|
| CJC-1295 DAC (weekly) | 1.0–2.0 mg |
| Ipamorelin (daily) | 100–300 mcg |
Route: Subcutaneous · Frequency: CJC-1295 DAC: once weekly | Ipamorelin: 2–3× daily · Cycle: 8–12 weeks
How It Works
CJC-1295 DAC provides sustained baseline GH elevation via long-acting GHRH receptor stimulation. Ipamorelin adds pulsatile GH bursts via ghrelin receptor activation. The combination creates both a sustained GH base and physiological GH pulses.
Potential Benefits
- •Sustained GH elevation (CJC-1295 DAC) plus pulsatile GH bursts (Ipamorelin).
- •Supports lean body composition, fat loss, and recovery.
- •Convenient once-weekly CJC-1295 DAC dosing.
Side Effects & Risks
- •Water retention.
- •Transient headache or flushing.
- •Prohibited by WADA.
Important Notes
- Keep vials separate — do not mix in the same syringe unless drawing immediately before injection.
- WADA prohibits both peptides.
Storage Instructions
- Both vials: Lyophilized −20 °C; once mixed 2–8 °C.
- Use within 14–21 days after mixing.
References
- [1]Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.